Equity Overview
Price & Market Data
Price: $28.33
Daily Change: -$1.16 / 4.09%
Daily Range: $28.33 - $28.42
Market Cap: $1,184,535,296
Daily Volume: 305,765
Performance Metrics
1 Week: 8.56%
1 Month: 8.56%
3 Months: 8.56%
6 Months: 8.56%
1 Year: 8.56%
YTD: -3.59%
About Avalyn Pharma Inc. (AVLN)
Comprehensive review of Avalyn Pharma Inc. (AVLN). Trading at 28.33, the stock has seen a daily change of -$1.16 / 4.09%. Its market capitalization is 1,184,535,296. All performance data is available for analysis.
Company Details
Employees: 50
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.